Treatment Outcomes of Squamous Cell Carcinoma of the Buccal Mucosa.
10.3342/kjorl-hns.2010.53.5.300
- Author:
Gye Song CHO
1
;
Jong Cheol LEE
;
Jong Lyel ROH
;
Seung Ho CHOI
;
Sang Yoon KIM
;
Soon Yuhl NAM
Author Information
1. Department of Otolaryngology, Asan Meidcal Center, University of Ulsan College of Medicine, Seoul, Korea. synam@amc.seoul.kr
- Publication Type:Original Article
- Keywords:
Mouth neoplasm;
Carcinoma;
Squamous cell;
Outcome;
Treatment
- MeSH:
Carcinoma, Squamous Cell;
Early Diagnosis;
Follow-Up Studies;
Humans;
Medical Records;
Mouth Mucosa;
Mouth Neoplasms;
Prognosis;
Retrospective Studies;
Survival Rate;
Treatment Failure;
Treatment Outcome
- From:Korean Journal of Otolaryngology - Head and Neck Surgery
2010;53(5):300-305
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND AND OBJECTIVES: Squamous cell carcinoma of the buccal mucosa (BMSCC) has been known to have poor prognosis characterized by a high locoregional failure rate. The purpose of this study is to assess the current treatment outcome and to estimate the prognostic factors in patients with BMSCC. SUBJECTS AND METHOD: We retrospectively reviewed the medical records of 20 patients who were diagnosed and treated for BMSCC between August 1996 and May 2008. Potential prognostic factors including age, gender, stage, histologic grade, treatment modality were evaluated. RESULTS: The 5-year overall survival and failure-free survival rate were 47% and 42%, respectively. The 3-year overall survival rate in the early staged carcinoma (stage I and II) was 76%, and in the advanced staged carcinoma (stage III and IV), 38% (p=0.022). Patients who had surgery as initial treatment or well differentiated cancer achieved better overall survival rates (p=0.003, p=0.018). Forty-five percent of patients had treatment failure during follow-up. The univariate analysis showed that clinical stages and histologic grades are the two most important prognostic factors responsible for treatment failure. CONCLUSION: The 5-year survival rate of BMSCC was 47%. The strong influence of disease stage on prognosis emphasizes the importance of early diagnosis of BMSCC and aggressive treatment for patients with poorly/moderated differentiated cancer.
